Drugs News and Research

RSS

China Pharmaceuticals first-quarter total revenue rises 50% to $7.05M

China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Behind the Numbers report: Employers' medical costs to increase by 9% in 2011

The nation's employers can expect medical costs to increase by 9 percent in 2011, a decrease of 0.5 percent from the 2010 growth rate, according to the annual Behind the Numbers report published today by the PricewaterhouseCoopers LLP Health Research Institute. For the first time, the majority of the American workforce is expected to have a health insurance deductible of $400 or more, as more employers return to "indemnity style" cost-sharing by raising out-of-pocket limits, replacing co-pays with co-insurance and adding high-deductible health plans.

15 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

'Micro-ear' to screen for malaria, sleeping sickness

A team of researchers from the Universities of Glasgow and Oxford, and the UK's National Institute of Medical Research at Mill Hill, are developing a 'micro-ear' which may help develop medicines and screening for diseases such as malaria and sleeping sickness in Africa. The project is in two parts, explains Professor Jon Cooper, a bio-engineer at University of Glasgow.

14 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

IMF concludes first-of-its-kind inaugural Myeloma Summit

The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, has concluded the first-of-its-kind inaugural Myeloma Summit meeting - nearly 70 of the world's leading experts in myeloma and related blood cancers charting the future of myeloma treatment and care.

14 Jun 2010

BioClinica eClinical Technology Suite and BIOP to be showcased at DIA Annual Meeting

BioClinica, Inc., a global provider of clinical trial management services, will exhibit at the 46th Drug Information Association Annual Meeting from June 13-17, 2010 in Washington, D.C., where it will showcase the BioClinica eClinical Technology Suite as well as introduce the BioClinica Integrated Operations Platform.

From Clario 14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Intellipharmaceutics International files Protonix ANDA with FDA

Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

14 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

News on the progress of a new trial may give new hope to patients with HIV who are dependent on anti-HIV drugs. The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from Atlanta-based, GeoVax Inc, a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Drugs News and Research

China Pharmaceuticals first-quarter total revenue rises 50% to $7.05M

Sulindac shuts down cancer cell growth, initiates cell death: Study

Pediatric oncologist describes current state of science in combating neuroblastoma

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Behind the Numbers report: Employers' medical costs to increase by 9% in 2011

New path involving "innocent spectators" to defeat systemic sclerosis

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

'Micro-ear' to screen for malaria, sleeping sickness

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

IMF concludes first-of-its-kind inaugural Myeloma Summit

BioClinica eClinical Technology Suite and BIOP to be showcased at DIA Annual Meeting

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Intellipharmaceutics International files Protonix ANDA with FDA

Monoclonal antibodies induce long-lasting, protective antiviral immune response

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

ARBs increase risk of cancer: Study

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News